GRI BIO, Inc. Files 8-K on Security Holder Votes
Ticker: GRI · Form: 8-K · Filed: Sep 6, 2024 · CIK: 1824293
Sentiment: neutral
Topics: corporate-governance, shareholder-meeting
TL;DR
GRI BIO (GRI) filed an 8-K for shareholder votes - check for updates on company decisions.
AI Summary
GRI BIO, Inc. (formerly Vallon Pharmaceuticals, Inc.) filed an 8-K on September 6, 2024, to report on matters submitted to a vote of its security holders. The company, incorporated in Delaware with its principal executive offices in La Jolla, CA, is in the pharmaceutical preparations industry.
Why It Matters
This filing indicates that GRI BIO, Inc. has held or is holding a meeting where shareholders will vote on important company matters, which could impact the company's future direction or governance.
Risk Assessment
Risk Level: low — This is a routine filing to report on shareholder votes, not indicating any immediate financial distress or significant operational change.
Key Numbers
- 001-40034 — SEC File Number (Identifies the company's filing history with the SEC.)
- 82-4369909 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- GRI BIO, Inc. (company) — Registrant
- Vallon Pharmaceuticals, Inc. (company) — Former company name
- September 6, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- La Jolla, CA (location) — Principal executive offices
FAQ
What specific matters were submitted for a vote by GRI BIO, Inc. security holders?
The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in the excerpt.
When was the name of the company changed from Vallon Pharmaceuticals, Inc. to GRI BIO, Inc.?
The date of the name change was September 10, 2020.
What is the primary business of GRI BIO, Inc.?
GRI BIO, Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.
Where are GRI BIO, Inc.'s principal executive offices located?
The principal executive offices are located at 2223 Avenida de la Playa, Suite 208, La Jolla, CA 92037.
What is the filing date of this Current Report on Form 8-K?
The filing date of this Current Report on Form 8-K is September 6, 2024.
Filing Stats: 740 words · 3 min read · ~2 pages · Grade level 14 · Accepted 2024-09-06 16:15:15
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share GRI The Nasdaq Capital Mark
Filing Documents
- val-20240906.htm (8-K) — 34KB
- val-20240906_g1.jpg (GRAPHIC) — 16KB
- val-20240906_g2.jpg (GRAPHIC) — 2KB
- 0001824293-24-000129.txt ( ) — 200KB
- val-20240906.xsd (EX-101.SCH) — 2KB
- val-20240906_def.xml (EX-101.DEF) — 3KB
- val-20240906_lab.xml (EX-101.LAB) — 24KB
- val-20240906_pre.xml (EX-101.PRE) — 15KB
- val-20240906_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders On September 6, 2024, GRI Bio, Inc. (the "Company") reconvened its 2024 Annual Meeting of Stockholders (the "Annual Meeting"), which was previously convened and adjourned on August 23, 2024, virtually at www.virtualshareholdermeeting.com/GRI2024. Of the Company's 741,914 shares of common stock issued and outstanding and eligible to vote as of the record date of June 27, 2024, a quorum of 311,668 shares, or approximately 42% of the eligible shares, was present in person or represented by proxy at the Annual Meeting. Each of the matters set forth below is described in detail in the Company's Definitive Proxy Statement filed with the Securities and Exchange Commission on August 2, 2024, as amended and supplemented to date. The following actions were taken at the Annual Meeting: Proposal 1 Election of David Baker to the Company's Board of Directors, to serve as Class I director until the Company's 2027 Annual Meeting of Stockholders and until his successor is duly elected and qualified. Votes For Votes Against Votes Abstained Broker Non-Votes 61,134 40,091 155 210,288 Proposal 2 Ratification of the appointment of Sadler, Gibb & Associates LLC as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. Votes For Votes Against Votes Abstained Broker Non-Votes 285,641 25,988 39 — Proposal 3 Approval, for purposes of complying with Nasdaq Rule 5635(d), of the issuance of shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"), underlying Series C-1 Common Warrants and Series C-2 Common Warrants issued by the Company pursuant to that certain Securities Purchase Agreement, dated as of June 26, 2024, by and between the Company and the investor named on the signature page thereto, and underlying Placement Agent Warrants issued by the Company pursuant to that certain Engagement Letter between the Company and H.C. Wainwright
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 6, 2024 GRI Bio, Inc. By: /s/ Leanne Kelly Leanne Kelly Chief Financial Officer